Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiome Tech Regulatory News (BIOM)

  • There is currently no data for BIOM

Trading Update

24 Apr 2019 07:00

RNS Number : 8674W
Biome Technologies PLC
24 April 2019
 

 

 

24 April 2019

 

Biome Technologies plc

("Biome", "the Company" or "the Group")

 

Trading Update

 

 

In advance of its Annual General Meeting today, Biome Technologies, a leading bioplastics and radio frequency technology business, is pleased to announce a trading update for the three months ended 31 March 2019.

 

Group revenues achieved for the first three months of the year were £2.1m, which is 11% ahead of the previous quarter (Q4 2018: £1.9m) and in line with those achieved in Q1 2018 (Q1 2018: £2.1m).

 

The Group made a small profit before interest, tax, depreciation, amortisation and share option charges in this quarter (based on unaudited management accounts).

 

The Group's cash position as at 31 March 2019 was £2.1m (31 December 2018: £2.6m), reflecting working capital movements.

 

Bioplastics Division

Revenues in the Bioplastics division for the first quarter rose significantly to £0.6m (Q1 2018: £0.4m; Q4 2018: £0.4m).

 

The improved performance was helped by both increased sales of outer packaging for the US single serve coffee market and by initial sales for a novel material for a single serve pod being launched into the nutrition market, previously reported as being under development. It is anticipated that sales for this latter application will gradually increase through the remainder of this year.

 

Progress on other projects, such as the rigid ring material and a plastic film based product for the North America market, remain on track with revenues for the rigid ring continuing to be anticipated to commence in Q2 2019 following completion of final testing.

 

Stanelco RF Technologies Division

Revenues for the first quarter of 2019 in the Stanelco RF division were £1.5m (Q1 2018: £1.7m; Q4 2018: £1.5m). The quarter was impacted positively by the delivery of multiple fibre optic furnaces which will not occur to the same extent in Q2.

 

In light of the current order book and general market outlook, the Board believes that revenues from this division for 2019 will be in line with previous guidance but more likely to be closer to those of 2017 than 2018, which was an exceptional year.

 

Outlook

2019 has commenced in an encouraging manner, particularly for the Bioplastics Division, and in line with the expectations set out in the Company's preliminary results announcement.

  

 

- Ends -

 

 

For further information please contact: Biome Technologies plc

 

Paul Mines, Chief Executive Officer

Declan Brown, Group Finance Director

www.biometechnologiesplc.com

Tel: +44 (0) 2380 867 100

 

Allenby Capital

David Hart/Alex Brearley (Nominated Adviser)

Kelly Gardiner (Broker)

www.allenbycapital.com

Tel: +44 (0) 20 3328 5656

 

 

 

 

About Biome

Biome Technologies plc is an AIM listed, growth-orientated, commercially driven technology group. Our strategy is founded on building market-leading positions based on patented technology and serving international customers in valuable market sectors. We have chosen to do this by developing products in application areas where the value-added pricing can be justified and that are not reliant on government legislation. These products are driven by customer requirements and are compatible with existing manufacturing processes. They are market rather than technology-led.

The Group comprises two divisions, Biome Bioplastics Limited and Stanelco RF Technologies Limited. Biome Bioplastics is a leading developer of highly-functional, bio-based and biodegradable plastics. The company's mission is to produce bioplastics that challenge the dominance of oil-based polymers. Stanelco RF Technologies designs, builds and services advanced radio frequency (RF) systems. Dielectric and induction heating products are at the core of a product offering that ranges from portable sealing devices to large furnaces for the fibre optics markets.

In 2018, the Board has adopted the following three high level KPIs for the next three years to continue its ambitious momentum:

· Compound revenue growth of 25% per annum across the Group and 40% compound revenue growth in the Bioplastics division

· Diversify the Group's turnover by product and market to ensure that no one product or end customer contributes more than 15% of revenues by 2020

· Increase investment in the Group's next generation of products by spending significantly more per annum on average than the £0.3m per annum average spend over the previous strategic objective cycle

 

www.biometechnologiesplc.com

www.biomebioplastics.com and www.thinkbioplastic.com 

www.stanelcorftechnologies.com

#ThinkBioplastic is our digital educational platform, launched in October 2018 in response to the emerging global plastic conversation. It speaks to a wide audience, highlighting bioplastics as a leading solution among several to reduce the negative impact of plastic manufacture and disposal. Following the much acclaimed first series of short videos the second series has just been released.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTCKNDBFBKDFQB
Date   Source Headline
21st Mar 20257:00 amRNSCancellation- Biome Technologies PLC
13th Mar 202512:22 pmRNSResult of GM & update on Cancellation
21st Feb 20257:00 amRNSProposed Cancellation & Notice of GM
18th Dec 20247:00 amRNSSecured Funding Facility
4th Dec 20247:00 amRNSTrading Update and Board Change
13th Nov 20247:00 amRNSTrading Update
25th Oct 20247:00 amRNSAppointment of Non-Executive Director
30th Sep 20245:00 pmRNSTotal Voting Rights
30th Sep 202411:08 amRNSContract win for Stanelco RF Division
20th Sep 20247:00 amRNSInterim Results
13th Sep 202410:58 amRNSHolding(s) in Company
12th Sep 202411:43 amRNSHolding(s) in Company
11th Sep 20243:01 pmRNSHolding(s) in Company
10th Sep 20247:00 amRNSHolding(s) in Company
9th Sep 20244:51 pmRNSHolding(s) in Company
4th Sep 20242:39 pmRNSResult of General Meeting and TVR
30th Aug 20245:00 pmRNSTotal Voting Rights
23rd Aug 20242:42 pmRNSHolding(s) in Company
22nd Aug 202411:00 amRNSHolding(s) in Company
22nd Aug 20247:00 amRNSResult of Retail Offer, Director dealing and TVR
21st Aug 20244:12 pmRNSHolding(s) in Company
21st Aug 20241:41 pmRNSHolding(s) in Company
16th Aug 20247:05 amRNSRetail offer to raise up to £80,000
16th Aug 20247:01 amRNSProposed Fundraise and other matters
16th Aug 20247:00 amRNSTrading update
10th Jul 20247:00 amRNSDirectorate Change
8th Jul 20247:00 amRNSTrading update
12th Jun 20247:00 amRNSGrant of Options
29th May 202410:57 amRNSResult of AGM, Interim CFO and Directorate Change
22nd May 20242:27 pmRNSContract win for Stanelco RF Division
15th May 20247:00 amRNSNotice of AGM and 2023 Annual Report
29th Apr 20247:01 amRNSTrading Update
29th Apr 20247:00 amRNSFinal Results 2023
15th Mar 20247:00 amRNSContract win for Stanelco RF Division
11th Mar 20241:59 pmRNSIssue of Convertible Loan Notes, PDMR Notification
15th Feb 20242:54 pmRNSContract win for RF Division
6th Feb 20247:00 amRNSTrading Update
13th Nov 20237:00 amRNSTrading Update
10th Oct 20234:32 pmRNSGrant of Options
27th Sep 20237:00 amRNSInterim Results
26th Jul 20237:00 amRNSTrading Update
30th Jun 20235:00 pmRNSTotal Voting Rights
22nd Jun 20237:00 amRNSContract win for Stanelco RF Division
31st May 20237:00 amRNSIssue of Equity, Director/PDMR Shareholding & TVR
25th May 20232:57 pmRNSAppointment of Non-Executive Director
25th May 202312:45 pmRNSResult of AGM
2nd May 20231:05 pmRNSDirector/PDMR Shareholding
27th Apr 20237:00 amRNSNotice of AGM and 2022 Annual Report
26th Apr 20237:01 amRNSTrading Update
26th Apr 20237:00 amRNSFinal Results 2022

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.